Memory CD8+ T cells are one of the most important players in mediating protective tumor immunity. The major goal of tumor immune therapy and immune vaccination including adoptive effector T cell and dendritic cell transfusion is to engender long-term protective memory CD8+ T cell immunity, and in turn results in tumor eradiation in patients with cancer. However, our current knowledge of memory T cells arises almost exclusively from studies of infectious disease models. The induction of memory T cells in cancer is often inadvertently thought of as being analogous to that observed in chronic infections. It is evident that the generation and function of memory T cells are dramatically impacted by the tumor microenvironment. We recently performed preliminary studies on the phenotype, functionality and epigenetic of memory CD8+ T cell subsets in human tumors. We have observed multiple phenotypically and functionally distinct memory CD8+ T cell subsets in ovarian cancer microenvironment. A number of unique clusters of genes were identified along with these memory CD8+ T cell subsets. Among these genes, the expression patterns of the polycomb group (PcG) protein like Enhancer of zeste homolog 2 (Ezh2), Ezh2-dependent trimethylation gene H3K27 (H3K27me3) and the target genes like Ezh2/Ink4a/Arf pathway are associated with particular CD8+ memory T cell subsets. Recent studies have revealed that Ezh2-dependent H3K27 trimethylation (H3K27me3) represses target genes like Ink4a/Arf to control growth, survival and renewal of cancer cells, cancer stem cells, ? cells and embryonic fibroblasts. However, the expression, regulation and role of Ezh2/Ink4a/Arf pathway have not been explored in immune cells including humans and mice. Our work suggests that epigenetic regulation plays a role in controlling memory T cell """"""""stemness"""""""" (proliferation, renewal and survival) and effector function of CD8+ memory T cell subsets in the tumor.
Our specific aims are:
Aim 1 is to test our hypothesis that ABCG2+CD8+ memory T cells exhibit the stem-like properties (stemness) in the OC microenvironment.
Aim 2 is to test our hypothesis that distinct epigenetic histone profiles are linked to specific CD8+ memory T cell subsets in the OC microenvironment.
Aim 3 is to test our hypothesis that the Ezh2/Ink4a/Arf pathway importantly determines the fate of CD8+ memory T cells, and that reprogramming this pathway engenders potent long-term anti-tumor immunity.

Public Health Relevance

Our understanding of memory CD8+ T cells in human tumor microenvironment lags much behind the more comprehensive analyses of these cells in infectious disease models. This deficiency significantly tempers our efforts toward understanding basic human memory T cell biology and potential application. The application takes a comprehensive approach by combining basic immunological methods, genetic and epigenetic research, and clinical and comparative analyses to address the nature of memory CD8+ T cells in the human tumor microenvironment. The application is conceptually and applicably significant, and will generate novel insight into new approaches in cancer immune therapy and vaccination.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA152470-03
Application #
8450202
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Mccarthy, Susan A
Project Start
2011-07-01
Project End
2016-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
3
Fiscal Year
2013
Total Cost
$369,459
Indirect Cost
$131,865
Name
University of Michigan Ann Arbor
Department
Surgery
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820
Nagarsheth, Nisha; Wicha, Max S; Zou, Weiping (2017) Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 17:559-572
Wang, Weimin; Kryczek, Ilona; Dostál, Lubomír et al. (2016) Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell 165:1092-1105
Zhao, Ende; Maj, Tomasz; Kryczek, Ilona et al. (2016) Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 17:95-103
Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65
Nagarsheth, Nisha; Peng, Dongjun; Kryczek, Ilona et al. (2016) PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Res 76:275-82
Zou, Weiping; Wolchok, Jedd D; Chen, Lieping (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4
Perusina Lanfranca, Mirna; Lin, Yanwei; Fang, Jingyuan et al. (2016) Biological and pathological activities of interleukin-22. J Mol Med (Berl) 94:523-34
Peng, Dongjun; Kryczek, Ilona; Nagarsheth, Nisha et al. (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249-53
Wan, Shanshan; Kuo, Ning; Kryczek, Ilona et al. (2015) Myeloid cells in hepatocellular carcinoma. Hepatology 62:1304-12

Showing the most recent 10 out of 20 publications